Lars Fruergaard Jørgensen, CEO of Novo Nordisk, will be questioned by US lawmakers regarding the high prices of the company’s diabetes and weight-loss drugs, including Ozempic and Wegovy. The hearing, scheduled for Tuesday, September 24th, is led by Senator Bernie Sanders who has been critical of the pharmaceutical industry’s pricing practices. Novo Nordisk is expected to defend its pricing, citing high development costs and insurance coverage, while critics point to the company’s significant profits and potential inclusion of their drugs in Medicare’s negotiated pricing program.